Answers are grounded in this paper and cite their sources.
Although the management of DD remains challenging, and the evidence for pharmacologic treatments is still unsatisfactory, cariprazine may be a candidate medication in DD due to its unique mechanism of action. Preliminary clinical experiences suggest that cariprazine has both antipsychotic and anticraving properties and should be considered early in patients with DD.
No takes yet. Share an insight, caveat, or question.
Heinz Grunze (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: